Manchester

Horizontal Tabs

Treatment Modalities 
Small Molecules
Immunotherapy
Gene therapy
Radiotherapy
Surgery
Chemoradiotherapy
Radioimmunotherapy
Facilities/Translational Research 

Phase I studies: including multicentre studies, and First-Time-In-Human studies.

Phase I population: adult solid tumours and haematology/lymphoma. Wide range of mechanisms studied. Areas of cancer specialism:

  • Lung
  • Lymphoma
  • Breast
  • Prostate
  • Colorectal
  • All solid tumours

Specific areas of translational research interest
  • Develop informative biomarkers (discovery, optimisation, validation, PK/PD, biological effective dose)
  • Develop and validate generic indicators of tumour apoptosis and anti-angiogenesis
  • Develop clinical proteomics/metabolomics
  • Conduct early phase Clinical Immunology trials and translational PD
  • Develop, integrate and expand imaging methodologies in preclinical models and early clinical trials
  • Increase capability to deliver targeted radiotherapies
  • Develop radiogenomics and image guided radiotherapy
  • Integrate GCLP compliant Laboratory QA systems into early clinical trials
Technology/equipment available within the centre

 

  • Pharmacodynamics and pharmacokinetics to GCLP
  • PET imaging, MRI imaging
  • Radiotracer design and manufacture
  • Genomics and molecular pathology
  • Proteomics
Sample collection
  • Multiple tumour specific banks
  • Integrated Banking facilities are in development within the MCRC

 

ECMC funding provides infrastructure support for early phase and translational research.  From the ECMC Manchester portfolio, the following trials have been carried out.
 
Trial activity between 2012-2015:
 
Trial by disease type between 2012-2015:

 

 

 

 

 

 

The Manchester ECMC has capability in world class biomedical imaging with its PET and MRI facilities located in both the Christie Trust and the on site Wolfson Imaging centre